| Qu, Xiujuan |
| Active, not recruiting | 3 | 408 | RoW | KN046, placebo | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Pancreatic Ductal Adenocarcinoma | 04/24 | 08/24 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
TQB2450-AL2846-III-01, NCT05922345: Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy. |
|
|
| Recruiting | 3 | 518 | RoW | TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules, TQB2450 placebo, docetaxel injection, AL2846 matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non-small Cell Lung Cancer | 08/25 | 12/25 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
NCT06206278: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma |
|
|
| Terminated | 2 | 6 | RoW | Infigratinib, BGJ398, BBP-831 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 05/24 | 05/24 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
NCT06666166: SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 28 | RoW | SHR-A1811 & Apartinib | Yunpeng Liu, Jiangsu HengRui Medicine Co., Ltd. | Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Colorectal Cancer | 07/28 | 12/28 | | |
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 498 | Europe, RoW | SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate | Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 10/26 | | |
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 320 | RoW | TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab | Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb | Advanced Cancer | 02/25 | 05/25 | | |
NCT04993391: AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 156 | RoW | JS111(AP-L1898 Capsules) | Suzhou Junjing BioSciences Co., Ltd. | Lung Cancer | 06/24 | 08/24 | | |
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
|
|
| Recruiting | 1/2 | 192 | RoW | CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC) | CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/24 | 06/38 | | |
NCT06500676: A Study of GFH375 in Patients with Advanced Solid Tumors with KRAS G12D Mutations |
|
|
| Recruiting | 1/2 | 290 | RoW | GFH375 | Genfleet Therapeutics (Shanghai) Inc. | KRAS G12D Mutations, Advanced Solid Tumors | 07/28 | 12/28 | | |
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 470 | US, RoW | IBI343 | Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed | Locally Advanced Unresectable or Metastatic Solid Tumors | 12/25 | 12/25 | | |
NCT06010901: A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer. |
|
|
| Recruiting | 1 | 75 | RoW | TQB2618 injection, Penpulimab injection, Anlotinib hydrochloride capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Colorectal Cancer | 03/25 | 07/25 | | |
NCT06050980: Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation |
|
|
| Recruiting | 1 | 220 | RoW | HSK40118 | Haisco Pharmaceutical Group Co., Ltd. | NSCLC | 08/25 | 06/27 | | |
| Recruiting | 1 | 150 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Breast Cancer | 12/25 | 12/26 | | |
NCT06463548: Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma |
|
|
| Not yet recruiting | N/A | 30 | RoW | irinotecan hydrochloride liposome injection, duoenyi, Capecitabine, Kapeitabin, Lenvatinib, lunfatini | Yunpeng Liu, CSPC Ouyi Pharmaceutical Co., Ltd. | Biliary Tract Carcinoma | 12/25 | 12/26 | | |
| Recruiting | N/A | 38 | RoW | Adebrelimab Injection, Apatinib Mesylate Tablets, Carboplatin, Cisplatin, Etoposide | Yunpeng Liu, Jiangsu HengRui Medicine Co., Ltd. | Small Cell Lung Cancer | 08/25 | 08/26 | | |
